title: In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
abstract: This study assessed the in vitro activities of ceftaroline and five comparator agents against a collection of Staphylococcus aureus isolates. Ceftaroline demonstrated potent activity against community-associated methicillin-resistant S. aureus (CA-MRSA) isolates and showed bactericidal activity against vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA), heteroresistant VISA (hVISA), and daptomycin-nonsusceptible S. aureus (DNSSA) isolates. Ceftaroline may represent a bactericidal treatment option for infections caused by these pathogens.
authors.affiliation: St. John Hospital and Medical Center, 19251 Mack Ave., Suite 333, Detroit, MI 48236, USA. louis.saravolatz@stjohn.org
authors.forename: Louis
authors.initials: L
authors.lastname: Saravolatz
authors.forename: Joan
authors.initials: J
authors.lastname: Pawlak
authors.forename: Leonard
authors.initials: L
authors.lastname: Johnson
mesh_terms: D002511:Cephalosporins / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D016106:Methicillin Resistance / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology*; D020713:Vancomycin Resistance / Q000187:drug effects*; D000097583:Ceftaroline
chemical_list: D002511:Cephalosporins; D017576:Daptomycin; D014640:Vancomycin; D000097583:Ceftaroline
references.citation: Antimicrob Agents Chemother. 2008 Mar;52(3):1153-5
references.pmid: 18180353
references.citation: Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8
references.pmid: 17620372
references.citation: Int J Antimicrob Agents. 2009 Jun;33(6):515-9
references.pmid: 19203863
references.citation: Antimicrob Agents Chemother. 2009 Nov;53(11):4712-7
references.pmid: 19738009
references.citation: Emerg Infect Dis. 2003 Aug;9(8):978-84
references.pmid: 12967497
references.citation: Clin Infect Dis. 2008 Mar 15;46(6):799-806
references.pmid: 18266610
references.citation: J Infect Chemother. 2004 Jun;10(3):146-56
references.pmid: 15290453
references.citation: Antimicrob Agents Chemother. 2009 Mar;53(3):1271-4
references.pmid: 19114671
references.citation: Emerg Infect Dis. 2006 Jun;12(6):894-9
references.pmid: 16707043
references.citation: Clin Infect Dis. 2004 May 1;38(9):1328-30
references.pmid: 15127350
references.citation: Antimicrob Agents Chemother. 2002 Apr;46(4):1147-52
references.pmid: 11897611
references.citation: Antimicrob Agents Chemother. 2005 Aug;49(8):3501-12
references.pmid: 16048970
references.citation: J Antimicrob Chemother. 2005 Dec;56(6):1047-52
references.pmid: 16239290
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3398-407
references.pmid: 18625769
references.citation: J Antimicrob Chemother. 2007 Aug;60(2):300-11
references.pmid: 17548456
references.citation: Clin Infect Dis. 2004 Feb 15;38(4):521-8
references.pmid: 14765345
references.citation: Clin Infect Dis. 2004 Feb 1;38(3):448-51
references.pmid: 14727222
references.citation: JAMA. 2003 Dec 10;290(22):2976-84
references.pmid: 14665659
references.citation: J Clin Microbiol. 2008 Sep;46(9):2950-4
references.pmid: 18632899
references.citation: Clin Infect Dis. 2006 Jun 1;42(11):1652-3
references.pmid: 16652325
references.citation: Antimicrob Agents Chemother. 1980 Nov;18(5):699-708
references.pmid: 7447427